These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 1977185)
1. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Riley SA; Turnberg LA Q J Med; 1990 Jun; 75(278):551-62. PubMed ID: 1977185 [No Abstract] [Full Text] [Related]
3. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases]. Kovács A Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465 [TBL] [Abstract][Full Text] [Related]
4. [New derivates of salazopyrine in the treatment of chronic inflammatory bowel disease]. Broide E; Scapa E; Abramowich D; Eshchar Y Harefuah; 1993 Feb; 124(4):223-5. PubMed ID: 8098698 [No Abstract] [Full Text] [Related]
5. [Salicylic derivatives in the clinical treatment of inflammatory bowel disease: new perspectives]. Damião AO; Sipahi AM Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(5):271-8. PubMed ID: 2576896 [TBL] [Abstract][Full Text] [Related]
6. Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease. Lauritsen K Dan Med Bull; 1989 Sep; 36(4):378-93. PubMed ID: 2572403 [No Abstract] [Full Text] [Related]
7. [5-ASA versus sulfasalazine]. Varela E Acta Gastroenterol Latinoam; 1994; 25(5):317-9. PubMed ID: 7785405 [No Abstract] [Full Text] [Related]
8. Drug insight: aminosalicylates for the treatment of IBD. Nielsen OH; Munck LK Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853 [TBL] [Abstract][Full Text] [Related]
9. [Experiences with phase III studies in the area of gastroenterology]. Kruis W Verh Dtsch Ges Inn Med; 1991; 97():503-6. PubMed ID: 1687301 [No Abstract] [Full Text] [Related]
10. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease]. Lukás K Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186 [No Abstract] [Full Text] [Related]
11. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. Kreisel W; Wolf LM; Grotz W; Grieshaber M Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875 [TBL] [Abstract][Full Text] [Related]
12. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Ryan BM; Russel MG; Langholz E; Stockbrugger RW Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319 [TBL] [Abstract][Full Text] [Related]
13. Update on the aminosalicylates: a promise fulfilled. Peppercorn MA Gastroenterology; 1988 Dec; 95(6):1677-80. PubMed ID: 2903113 [No Abstract] [Full Text] [Related]
14. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Xin H; Fischer C; Schwab M; Klotz U Aliment Pharmacol Ther; 2005 May; 21(9):1105-9. PubMed ID: 15854172 [TBL] [Abstract][Full Text] [Related]
18. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome. Tebano MT; Traversa G; Da Cas R; Loizzo A Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773 [TBL] [Abstract][Full Text] [Related]